Genetic Technologies

Genetic Technologies

Genetic Technologies originated in Fitzroy, Australia, as a genomics research entity with more than 20 years of work tracing back to the human genome project. On 24 December 2024, Rhythm Biosciences acquired the geneType business assets, folding the brand into a publicly traded diagnostics company. The combined entity now operates as a single commercial platform marketing disease-risk tests directly through physicians. The geneType platform spans at least ten disease areas. Its assessments cover breast cancer, colorectal cancer, ovarian cancer, prostate cancer, pancreatic cancer, melanoma, coronary artery disease, type 2 diabetes, and atrial fibrillation, plus a multi-risk suite that bundles several conditions. Every test starts with a buccal or saliva sample and returns lifetime and 10-year absolute risk scores. The algorithms combine polygenic risk scores with clinical risk factors such as family history, body mass index, and age. The company states its breast-cancer and colorectal-cancer models outperform the clinical gold-standard risk calculators currently in use. Distribution runs solely through medical practitioners; patients cannot order tests directly. The firm does not disclose revenue, asset base, or team headcount. Its Fitzroy headquarters remains its only known office. Adjacent vehicles or operating subsidiaries have not been identified. In December 2024, Rhythm Biosciences completed the asset acquisition agreement for the geneType business, initiating an integration process that is still underway (per the company, December 2024). No subsequent funding rounds, product launches, or partnership announcements have been captured. Genetic Technologies occupies a narrow regulatory niche: it sells laboratory-developed tests that clinicians must order, putting it outside direct-to-consumer channels. Its scientific heritage and the December 2024 acquisition give it a publicly listed parent, which creates a disclosure requirement most private diagnostics startups lack. That structure may surface operational metrics over time, but for now the newly combined entity remains materially opaque.